{
  "docId": "019de075-2cce-7280-b26a-b6cf6a81cc60",
  "docSlug": "0ebab7f84cc526493dad2db7df8c89e5",
  "documentTitle": "MindMed | Investor Day Presentation Deck | 61 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 61,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a screenshot of a press release as evidence of the enrollment milestone.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2cce-7280-b26a-b6cf6a81cc60/11",
  "deckHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60",
  "deckJsonHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60.json",
  "deckAnchorHref": "/decks/019de075-2cce-7280-b26a-b6cf6a81cc60#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.32,
        "x": 0.63,
        "y": 0.3
      },
      "kind": "image",
      "text": "MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdaa5166-b0e5-4708-821c-93129d419a7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "Phase 2a in ADHD | Topline readout late 2023: 52-patient Phase 2a proof-of-concept trial to assess safety and efficacy of repeated low-dose MM-120 administration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67ff8334-0888-4503-882e-ce1d89d97edf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Phase 2b in GAD | Topline readout late 2023: 200-patient Phase 2b dose-optimization trial to assess safety, determine effect size and inform dose selection for pivotal Phase 3 studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0f34d8c-bf66-4f93-a25a-a3908ab02031",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "We are positioned for two key data readouts this year and have recently reached an enrollment milestone in our Phase 2b trial for GAD with over 50% of patients dosed across 20 active clinical sites",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91f61f68-886c-4a1b-9f01-cc82ffd4d6e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "subtitle",
      "text": "Proprietary drug candidate with evidence of clinical benefits across a broad range of brain health disorders",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1db9c4d5-3e11-4b34-8f1f-7ef9e945c201",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Key Drug Candidate: MM-120 Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d38d7499-1787-463e-ad32-456439ba858c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "02740e2c-af7f-452b-a3ae-53378edc3924",
      "evidence": "We are positioned for two key data readouts this year and have recently reached an enrollment milestone in our Phase 2b trial for GAD with over 50% of patients dosed across 20 active clinical sites",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 11,
      "beatId": "26f48ee6-c9c3-455a-9b0e-455a881dc5a5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The presentation showcases MM-120 as a key product candidate.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}